TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03886597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table Olives
Description: At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table Olives
Description: At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Table Olives
Description: All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
Study: NCT03599622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02026245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Data gloves to perform movements
Description: Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Data gloves to perform movements
Description: Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove
Study: NCT01395511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Tool : Acupuncture Seirin SJ 0.16 \* 40 (mm) / SJ 0.18 \* 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN
Study: NCT02136771

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03159078

Intervention type: DRUG
Group type: OTHER
Intervention: Polymyxin B
Description: Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
Study: NCT02319863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatectomy (conventional method)
Description: A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatectomy (rapid ligating)
Study: NCT02562092

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reducing Risk Behavior
Description: A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support and Guidance
Description: A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
Study: NCT00994799

Intervention type: DRUG
Intervention: ranibizumab
Description: 10mg/ml intravitreal injection

Intervention type: RADIATION
Intervention: macular grid-pattern laser
Description: macular grid-pattern laser therapy
Study: NCT01915524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9202
Description: Intradermal injection of CV9202

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: local radiation
Description: Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
Study: NCT02802644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non DPP-4 Inhibitor
Description: This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
Study: NCT01621971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled milrinone
Description: After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous milrinone
Description: After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
Study: NCT01580176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous GlucoseMonitor
Description: The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
Study: NCT02925377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up
Description: The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard warm-up
Description: Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
Study: NCT01069315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage solution
Description: Comparison of castile soap solution vs. normal saline solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage solution
Description: Comparison of castile soap solution vs. normal saline solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage solution
Description: Comparison of castile soap solution vs. normal saline solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage solution
Description: Comparison of castile soap solution vs. normal saline solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage pressure
Description: Comparison of low pressure vs. high pressure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage pressure
Description: Comparison of low pressure vs. high pressure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage pressure
Description: Comparison of low pressure vs. high pressure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of fluid lavage pressure
Description: Comparison of low pressure vs. high pressure.
Study: NCT00458575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 2476
Description: Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
Study: NCT04108780

Intervention type: DEVICE
Intervention: T-tube
Description: T shaped tube used as stent after CBD exploration

Intervention type: DEVICE
Intervention: T-tube
Description: T shaped tube used as stent after CBD exploration
Study: NCT00931827

Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Patients under daily life treatment receiving Mirena according to local drug information.

Intervention type: DRUG
Intervention: Implanon (Etonogestrel)
Description: Patients under daily life treatment receiving Implanon according to local drug information.
Study: NCT01924637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days.
Study: NCT04651309

Intervention type: OTHER
Group type: OTHER
Intervention: Transperineal Ultrasound
Description: The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
Study: NCT00027976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study: NCT02507843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in placebo group monthly for 6 months.
Study: NCT04851418

Intervention type: DEVICE
Intervention: Possible NSTE-ACS
Description: As mentioned in the group description
Study: NCT00997022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)
Study: NCT04283474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005-03
Description: 3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical formulation
Study: NCT05475457

Intervention type: BEHAVIORAL
Intervention: R3
Description: Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.

Intervention type: BEHAVIORAL
Intervention: R3
Description: Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
Study: NCT04257253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted exercise program
Description: Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercise program
Description: Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
Study: NCT01846806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
Study: NCT03174691

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone.
Study: NCT01631838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction 400mg
Description: Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
Study: NCT02764203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: 50g dark chocolate consumed for a period of 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable devices
Description: Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
Study: NCT00347321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilatational Percutaneous tracheostomy
Description: Dilatational Percutaneous tracheostomy
Study: NCT04080089

Intervention type: COMBINATION_PRODUCT
Intervention: Surgical treatment, drug therapy, remote cognitive training
Description: Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment.
Study: NCT00027976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03043482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single VS-105/placebo to healthy
Description: In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
Study: NCT02978885

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT CT

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT-CT imaging
Description: Injection of AxV-128 labeled with 99mTc followed by SPECT CT

Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc

Intervention type: DRUG
Group type: OTHER
Intervention: AxV-128/Tc
Description: Injection of AxV-128 labeled with 99mTc

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whipple procedure
Description: A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whipple procedure
Description: A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Major surgery
Description: Additional surgical procedure(s) that is clinically indicated. Standard of care.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Major surgery
Description: Additional surgical procedure(s) that is clinically indicated. Standard of care.
Study: NCT03286231

Intervention type: DIAGNOSTIC_TEST
Intervention: CT imaging
Description: Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
Study: NCT03217968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly® Abortive Program device
Description: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
Study: NCT01446250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: BOC 800 mg (4 x 200 mg soft gel capsules) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT01273155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
Study: NCT03043482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple VS-105/placebo to healthy
Description: In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
Study: NCT01273155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
Study: NCT03043482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple VS-105/placebo to HD subjects
Description: In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
Study: NCT01273155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).